Amneal Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03168L1052

SecurityAMRX / Amneal Pharmaceuticals, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership1,719,954 shares
Latest Disclosed Value $ 21,379,029
D. E. Shaw & Co., Inc. reports 35.39% decrease in ownership of AMRX / Amneal Pharmaceuticals, Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 1,719,954 shares of Amneal Pharmaceuticals, Inc. (US:AMRX) valued at $21,379,028 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 2,661,854 shares of Amneal Pharmaceuticals, Inc.. This represents a change in shares of -35.39% during the quarter. The current value of the position is $22,144,408 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,719,954 -941,900 -35.39 21,379 -36.26 0.0129
2026-02-17 2025-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 2,661,854 1,096,643 70.06 33,539 114.07 0.0184
2025-11-14 2025-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,565,211 641,567 69.46 15,668 109.68 0.0088
2025-08-14 2025-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 923,644 907,808 5,732.56 7,472 5,560.61 0.0053
2025-05-15 2025-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 15,836 15,836 133 0.0001
2024-11-14 2024-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -89,895 -100.00 0 -100.00
2024-08-14 2024-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 89,895 -136,309 -60.26 571 -58.39 0.0005
2024-05-15 2024-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 226,204 -439,832 -66.04 1,371 -66.11 0.0012
2024-02-14 2023-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 666,036 -208,880 -23.87 4,043 9.48 0.0035
2023-11-14 2023-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 874,916 252,690 40.61 3,692 91.49 0.0039
2023-08-14 2023-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 622,226 -7,883 -1.25 1,929 120.34 0.0020
2023-05-15 2023-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 630,109 -58,728 -8.53 876 -36.13 0.0009
2023-02-14 2022-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 688,837 427,987 164.07 1,371 159.96 0.0015
2022-11-14 2022-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 260,850 71,923 38.07 527 -12.31 0.0006
2022-08-15 2022-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 188,927 -65,072 -25.62 601 -43.25 0.0007
2022-05-16 2022-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 253,999 95,977 60.74 1,059 39.89 0.0010
2022-02-14 2021-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 158,022 139,980 775.86 757 688.54 0.0006
2021-11-15 2021-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 18,042 18,042 96 0.0001
2021-08-16 2021-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -122,774 -100.00 0 -100.00
2021-05-17 2021-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 122,774 122,774 826 0.0008
2020-05-15 2020-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -224,285 -100.00 0 -100.00
2020-02-14 2019-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 224,285 125,081 126.08 1,081 275.35 0.0012
2019-11-14 2019-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 99,204 -59,475 -37.48 288 -74.69 0.0004
2019-08-14 2019-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 158,679 -265,301 -62.57 1,138 -81.06 0.0014
2019-05-15 2019-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 423,980 -378,882 -47.19 6,008 -44.69 0.0078
2019-02-14 2018-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 802,862 56,890 7.63 10,863 -34.37 0.0150
2018-11-14 2018-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 745,972 -246,020 -24.80 16,553 1.68 0.0199
2018-08-14 2018-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 991,992 991,992 16,279 0.0212
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.